The Effect of Sitagliptin, Pioglitazone and other glucose Lowering Drugs on Inflammatory and Coagulative Factors and Lipid Profile in Type II Diabetes Patients

Abstract

The aim of current study is to evaluate the effect of adding pioglitazone or sitagliptin to combination therapy of metformin and sulfonylurea on glycemic control, lipid profile and inflammatory markers. Methods: In this randomized clinical trial, 125 patients with DM2 under treatment with metformin and sulfonylurea were randomly allocated to three groups. First group received sitagliptin 100 mg (n=45), second group received pioglitazone 30 mg (n=40) added to former treatment and the third group continued treatment with metformin and sulfonylurea (n=40) for three months. At the end of the study, anthropometric variables, HbA1c, lipid profile, fibrinogen and HsCRP were compared between groups. Results: Sitagliptin group compared to pioglitazone and control group had significantly lower HsCRP (0.53±0.26 vs. 2.44±0.52 vs. 4.43±1.94, p<0.001 for both) and fibrinogen (314.08±48.09 vs. 340.92±65.1 [p=0.03] and vs. 346.35±60.69 [p=0.01]).Pioglitazone group compared to sitagliptin and control groups had significantly lower triglyceride levels (115.02±32.92 vs. 159.53±66.83 [p=0.002] and vs. 171.75±79.76 [p<0.001]) and higher HDL levels (51.57±11.14 vs. 41.51±7.71 [p<0.001] and vs.44.18±11.09 [p=0.001]). There was no difference between groups regarding weight.